EUVIMEDEUVIMED entdecken
Crossref

Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence

Maria Tamburo, Emanuele Buffettino, Pietro Pepe, Giulia Marletta, Ludovica Pepe, Sebastiano Cosentino, Massimo Ippolito, Michele Pennisi, Francesco Marletta

Anticancer Research · 2024

DOI: 10.21873/anticanres.17027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Maria Tamburo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Radiotherapy Unit, Cannizzaro Hospital, Catania, Italy; marinellatamburo@virgilio.it. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Prostate-Specific Antigen, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: To evaluate the clinical outcome in men with recurrent prostate cancer (PCa) treated by salvage radiotherapy (sRT) prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)-guided. PATIENTS AND METHODS: From January 2021 to January 2023, 33 patients who previously underwent definitive/systemic therapy were submitted to sRT PSMA PET/CT-guided for PCa recurrence: 16 (48.5%) on the prostate bed (PB), 12 (36.4%) on the lymph node (LN) and five (15.1%) on the bone. The median PSA value was 3.3 ng/ml (range=0.3-15.5 ng/ml): 0.2-0.5 ng/ml (18.2% cases), 0.51-1 ng/ml (39.4% cases) and >1 ng/ml (42.4% cases). Median 18F PSMA PET/CT standardized uptake value (SUVmax) was evaluated on PB, vs. LN vs. bones PCa recurrences and was equal to 12.5 vs. 19.0 vs. 30.1, respectively. RESULTS: Overall, at a median follow up of 12 months, 23/33 patients (69.7%) had local control without distant progression (PSA and SUVmax evaluation): 14/16 (87.5%) vs. 7/12 (58.3%) vs. 2/5 (40%) underwent sRT on the PB vs. LN vs. bone metastases, respectively. CONCLUSION: PSMA PET/CT allows to perform sRT early in men with PCa recurrence and low PSA values obtaining a complete clinical response in approximately 70% of the cases one year from treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsProstate-Specific AntigenNeoplasm Recurrence, LocalSalvage TherapyHumansMaleAgedMiddle AgedAged, 80 and overGlutamate Carboxypeptidase IIAntigens, SurfaceRadiotherapy, Image-Guided

Stichwörter der Autor:innen

PCa recurrencePSA failurePSMA PET/CTSalvage radiotherapy

Substanzen

Prostate-Specific AntigenFOLH1 protein, humanGlutamate Carboxypeptidase IIAntigens, Surface

Autor:innen und Institutionen

  • Radiotherapy Unit, Cannizzaro Hospital, Catania, Italy; marinellatamburo@virgilio.it.
  • Radiotherapy Unit, Cannizzaro Hospital, Catania, Italy.
  • Urology Unit, Cannizzaro Hospital, Catania, Italy.
  • Nuclear Medicine Unit, Cannizzaro Hospital, Catania, Italy.

Zitieren

APA

Tamburo, M., Buffettino, E., Pepe, P., Marletta, G., Pepe, L., Cosentino, S., Ippolito, M., Pennisi, M., & Marletta, F. (2024). Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence. Anticancer Research. https://doi.org/10.21873/anticanres.17027

Vancouver

Tamburo M, Buffettino E, Pepe P, Marletta G, Pepe L, Cosentino S, et al. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence. Anticancer Research. 2024. doi:10.21873/anticanres.17027

BibTeX
@article{Tamburo2024,
  author = {Tamburo, Maria and Buffettino, Emanuele and Pepe, Pietro and Marletta, Giulia and Pepe, Ludovica and Cosentino, Sebastiano and Ippolito, Massimo and Pennisi, Michele and Marletta, Francesco},
  title = {Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17027}
}
Kostenlos starten →